Bollard Catherine 4

What Happened
Catherine Bollard, a member of Cabaletta Bio's board of directors, was granted a derivative award on June 9, 2026 representing the right to acquire 22,000 shares. The reported acquisition price is $0.00, indicating an equity award/option rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Filing date: 2026-06-10 (timely filing).
• Transaction type: Award/Grant of derivative securities (Form 4 code A).
• Amount: 22,000 shares (derivative), acquisition price reported as $0.00.
• Vesting: Award vests in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of stockholders (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No sale or cash purchase occurred; this is a grant of rights to acquire shares in the future.

Context
This is an equity award to a director rather than an open-market trade. Because the award vests over time (or upon the next annual meeting), it does not reflect an immediate purchase or sale. Retail investors should view this as a compensation/retention grant; it does not by itself indicate insider buying or selling of stock for liquidity.